Inhibin B – Evaluation of laboratory reference values in children and adolescents as well as a statement to validity and clinical appliance in pediatric diabetology and pediatric cancer survivors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015263

Enrollment

200

Registered

2018-08-27

Start date

2018-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

study for standard/normal values E10.90 E89.9 Z08.9

Interventions

Group 1: other, non-interventionell, first cohort (healthy children and adolescents < 20 years), 4.7 ml blood, 1 specimen Group 2: other, non-interventionell, second cohort (pediatric Diabetes < 2

Eligibility

Sex/Gender

All

Age

No minimum to 20 Years

Inclusion criteria

Inclusion criteria: including criteras: • informed consent • Aged < 20 years • no other relevant disease • patients with Diabetes mellitus • patients after cancer therapy, as well as after stem cell transplantation

Exclusion criteria

Exclusion criteria: excluding criterias: • aged = 20 years at start of study • acute disease • other chronic disease (HIV, Tbc) • pregnancy • substance abuse • parents beeing unable to understand the subject of the study • participation in another AMG study

Design outcomes

Primary

Measure	Time frame
In this study standard values for Inhibin B will be described as well as an interpretation will be given for Inhibin B in chronic health conditions of pediatric patients with diabetes mellitus and in young survivors of childhood cancer disease. The newly developed Assay „Inhibin B Gen II ELISA“ may differentiate between structural subgroups of Inhibin B and perform a more accurate measurement since before.	—

Measure

Time frame

In this study standard values for Inhibin B will be described as well as an interpretation will be given for Inhibin B in chronic health conditions of pediatric patients with diabetes mellitus and in young survivors of childhood cancer disease. The newly developed Assay „Inhibin B Gen II ELISA“ may differentiate between structural subgroups of Inhibin B and perform a more accurate measurement since before.

—

Countries

Germany

Contacts

Public ContactUlrich Paetow

KKJM, UK FfM

ulrich.paetow@kgu.de089 6301 7690

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026